Ad
related to: clinical data inc stock split
Search results
Results From The WOW.Com Content Network
In January 2019, NantHealth received a delisting warning from Nasdaq "because the Company’s common stock failed to maintain a minimum closing bid price of $1.00 for 30 consecutive business days." [11] At the time, the market value of the company was approximately $57m. [12] The company made a 1-for-15 reverse stock split in December, 2022. [13]
In May 2016, the company announced it would merge with Quintiles [21] [22] IMS Health shareholders received 0.384 shares of Quintiles common stock for each share of IMS Health common stock they held, leaving the split of ownership at 51.4% IMS and 48.6% Quintiles.
[28] [29] IMS Health shareholders received 0.384 shares of Quintiles common stock for each share of IMS Health common stock they held, leaving the split of ownership at 51.4% IMS and 48.6% Quintiles. [ 30 ] [ 31 ] The merger was completed in October and the resulting company was a $17.6 billion company called QuintilesIMS. [ 9 ]
Tuesday, Trinity Biotech plc (NASDAQ:TRIB) stock is trading higher with a session volume of 14.32 million versus the average volume of 118.9K as per data from Benzinga Pro. The company received ...
ServiceNow has never split its stock nor indicated it will. If it initiated a 10-for-1 split similar to Broadcom's, each share at approximately $800 per share would become 10 shares at $80 per share.
The main effect of stock splits is an increase in the liquidity of a stock: [3] there are more buyers and sellers for 10 shares at $10 than 1 share at $100. Some companies avoid a stock split to obtain the opposite strategy: by refusing to split the stock and keeping the price high, they reduce trading volume.
For example, a 10-1 stock split of Nvidia trading at $1,020 per share would bring the price down to $102 per share. What is a stock split and how does it impact investors?
As yet unpublished pre-clinical data indicate that Poly-ICR, in combination with a tumor-associated antigen, increases antigen-specific CD8 T-cell levels, while both inducing regression of tumors and preventing tumor growth in mouse models. [4] The company developed Poly-ICR for both internal use and for external licensing opportunities.